Varicella zoster virus-associated morbidity and mortality in Africa – a systematic review
dc.contributor.author | Hussey, Hannah | |
dc.contributor.author | Abdullahi, Leila | |
dc.contributor.author | Collins, Jamie | |
dc.contributor.author | Muloiwa, Rudzani | |
dc.contributor.author | Hussey, Gregory | |
dc.contributor.author | Kagina, Benjamin | |
dc.date.accessioned | 2017-12-15T07:22:01Z | |
dc.date.available | 2017-12-15T07:22:01Z | |
dc.date.issued | 2017-11-14 | |
dc.date.updated | 2017-11-19T04:26:29Z | |
dc.description.abstract | Background: Varicella zoster virus (VZV) causes varicella and herpes zoster. These vaccine preventable diseases are common globally. Most available data on VZV epidemiology are from industrialised temperate countries and cannot be used to guide decisions on the immunization policy against VZV in Africa. This systematic review aims to review the published data on VZV morbidity and mortality in Africa. Methods: All published studies conducted in Africa from 1974 to 2015 were eligible. Eligible studies must have reported any VZV epidemiological measure (incidence, prevalence, hospitalization rate and mortality rate). For inclusion in the review, studies must have used a defined VZV case definition, be it clinical or laboratory-based. Results: Twenty articles from 13 African countries were included in the review. Most included studies were crosssectional, conducted on hospitalized patients, and half of the studies used varying serological methods for diagnosis. VZV seroprevalence was very high among adults. Limited data on VZV seroprevalence in children showed very low seropositivity to anti-VZV antibodies. Co-morbidity with VZV was common. Conclusion: There is lack of quality data that could be used to develop VZV control programmes, including vaccination, in Africa. Trial registration: PROSPERO 2015: CRD42015026144. | |
dc.identifier.apacitation | Hussey, H., Abdullahi, L., Collins, J., Muloiwa, R., Hussey, G., & Kagina, B. (2017). Varicella zoster virus-associated morbidity and mortality in Africa – a systematic review. <i>BMC Infectious Diseases</i>, http://hdl.handle.net/11427/26713 | en_ZA |
dc.identifier.chicagocitation | Hussey, Hannah, Leila Abdullahi, Jamie Collins, Rudzani Muloiwa, Gregory Hussey, and Benjamin Kagina "Varicella zoster virus-associated morbidity and mortality in Africa – a systematic review." <i>BMC Infectious Diseases</i> (2017) http://hdl.handle.net/11427/26713 | en_ZA |
dc.identifier.citation | Hussey, H., Abdullahi, L., Collins, J., Muloiwa, R., Hussey, G., & Kagina, B. (2017). Varicella zoster virus-associated morbidity and mortality in Africa–a systematic review. BMC infectious diseases, 17(1), 717. | |
dc.identifier.ris | TY - Journal Article AU - Hussey, Hannah AU - Abdullahi, Leila AU - Collins, Jamie AU - Muloiwa, Rudzani AU - Hussey, Gregory AU - Kagina, Benjamin AB - Background: Varicella zoster virus (VZV) causes varicella and herpes zoster. These vaccine preventable diseases are common globally. Most available data on VZV epidemiology are from industrialised temperate countries and cannot be used to guide decisions on the immunization policy against VZV in Africa. This systematic review aims to review the published data on VZV morbidity and mortality in Africa. Methods: All published studies conducted in Africa from 1974 to 2015 were eligible. Eligible studies must have reported any VZV epidemiological measure (incidence, prevalence, hospitalization rate and mortality rate). For inclusion in the review, studies must have used a defined VZV case definition, be it clinical or laboratory-based. Results: Twenty articles from 13 African countries were included in the review. Most included studies were crosssectional, conducted on hospitalized patients, and half of the studies used varying serological methods for diagnosis. VZV seroprevalence was very high among adults. Limited data on VZV seroprevalence in children showed very low seropositivity to anti-VZV antibodies. Co-morbidity with VZV was common. Conclusion: There is lack of quality data that could be used to develop VZV control programmes, including vaccination, in Africa. Trial registration: PROSPERO 2015: CRD42015026144. DA - 2017-11-14 DB - OpenUCT DO - 10.1186/s12879-017-2815-9 DP - University of Cape Town J1 - BMC Infectious Diseases LK - https://open.uct.ac.za PB - University of Cape Town PY - 2017 T1 - Varicella zoster virus-associated morbidity and mortality in Africa – a systematic review TI - Varicella zoster virus-associated morbidity and mortality in Africa – a systematic review UR - http://hdl.handle.net/11427/26713 ER - | en_ZA |
dc.identifier.uri | http://dx.doi.org/10.1186/s12879-017-2815-9 | |
dc.identifier.uri | http://hdl.handle.net/11427/26713 | |
dc.identifier.vancouvercitation | Hussey H, Abdullahi L, Collins J, Muloiwa R, Hussey G, Kagina B. Varicella zoster virus-associated morbidity and mortality in Africa – a systematic review. BMC Infectious Diseases. 2017; http://hdl.handle.net/11427/26713. | en_ZA |
dc.language.iso | en | |
dc.publisher | BioMed Central | |
dc.publisher.department | Division of Medical Microbiology | en_ZA |
dc.publisher.faculty | Faculty of Health Sciences | en_ZA |
dc.publisher.institution | University of Cape Town | |
dc.rights.holder | The Author(s). | |
dc.source | BMC Infectious Diseases | |
dc.source.uri | https://bmcinfectdis.biomedcentral.com/ | |
dc.subject.other | Varicella | |
dc.subject.other | Zoster | |
dc.subject.other | Shingles | |
dc.subject.other | Chickenpox | |
dc.subject.other | Africa | |
dc.subject.other | Epidemiology | |
dc.title | Varicella zoster virus-associated morbidity and mortality in Africa – a systematic review | |
dc.type | Journal Article | |
uct.type.filetype | Text | |
uct.type.filetype | Image |